Valerio Therapeutics
C4X
Company Profile
Business description
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using two proprietary platforms: the PlatON platform and its DNA decoy mechanism of action, and the V-Body platform generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-ofconcept, a value-creating inflection point appealing to potential partners. Its pipline includes Metabolic Diseases, Immunology & Inflammatory, and Oncology.
Contact
49, Boulevard du General
Martial Valin
Paris75015
FRAT: +33 145587600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
38
Stocks News & Analysis
stocks
Perplexing buyback from overvalued ASX share
Earnings continue to grow but investor expectations are too high.
stocks
Most popular shares in SMSFs
With data showing the continued rise of SMSFs, we explore the top stock picks of individual investors
stocks
Will China strong arm BHP into lower iron ore prices?
Allegations that the Chinese government told steel mills to stop buying from BHP shake markets.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,208.50 | 9.00 | -0.10% |
| CAC 40 | 7,851.76 | 82.50 | -1.04% |
| DAX 40 | 24,076.20 | 311.73 | -1.28% |
| Dow JONES (US) | 46,067.58 | 587.98 | 1.29% |
| FTSE 100 | 9,403.26 | 39.61 | -0.42% |
| HKSE | 25,441.35 | 448.13 | -1.73% |
| NASDAQ | 22,694.61 | 490.18 | 2.21% |
| Nikkei 225 | 46,847.32 | 1,241.48 | -2.58% |
| NZX 50 Index | 13,276.99 | 74.93 | -0.56% |
| S&P 500 | 6,654.72 | 102.21 | 1.56% |
| S&P/ASX 200 | 8,899.40 | 10.30 | -0.12% |
| SSE Composite Index | 3,865.23 | 24.27 | -0.62% |